Strata Critical Medical (SRTA) Stock Fundamentals, Analysis & Risk Signals

Health score, price, valuation, risk signals, and key metrics at a glance.

Strata Critical Medical

NasdaqCM•Healthcare•Medical Care Facilities

$6.12-0.07(-0.01%)After hours

Market Cap

$463.83M

P/E

11.5x

P/S

2.2x

P/B

1.7x

Strata Critical Medical, Inc. provides time-critical logistics and medical services to the healthcare industry in the United States. It operates in two segments, Logistics and Clinical. The company offers logistics services, such as air and ground transportation for human organs, transplant teams, and related medical materials and organ placement services; transplant clinical services, including organ recovery procedures, normothermic regional perfusion, and preservation services. It also provides other clinical services comprising cardiac perfusion services, blood management and autotransfusion services, extracorporeal membrane oxygenation services, perfusion staffing, and equipment rentals. The company was formerly known as Blade Air Mobility, Inc. and changed its name to Strata Critical Medical, Inc. in August 2025. The company was founded in 2014 and is headquartered in New York, New York.

How this company scores

AverageMetricSide Score: 42/100

Strongest: Balance Sheet & Red Flags (15/25); weakest: Cash & Earnings Quality (7/25).

Profitability12/25

Growth8/25

Balance Sheet & Red Flags15/25

Cash & Earnings Quality7/25

Strengths

Rising earningsInterest easily coveredProfit converts from growthNet cash position

Valuation vs. 5-year range

Today's multiple positioned against its own trailing range — a visual premium/discount check.

P/E · 11.5x5y range 7.4x – 11.5x

Currently near its 4-quarter median.

P/S · 2.2x5y range 0.9x – 44.7x

Currently above its 20-quarter median.

P/B · 1.7x5y range 0.7x – 2.2x

Watch items

Data-driven signals worth keeping an eye on across the last 8 quarters

High Risk

Margin Pressure

Red Flag

The company posted negative operating margins in recent quarters — core operations are unprofitable.

Earnings Quality

Red Flag

Free cash flow has been negative in 7 of the last 8 quarters — earnings are not translating to cash.

Price & Volume

Market Cap $463.83M

Metrics at a Glance

as of June 2026

Revenue & Profit

Revenue, EBITDA, operating income, net income, EPS, and shares

TTM Revenue: $211.92M
Q. Revenue: $72.51M
TTM EBITDA: $-1.91M
TTM Op. Income: $-18.20M
Q. Op. Income: $-5.41M
TTM Net Income: $40.22M
Q. Net Income: $-10.52M
EPS: $-0.12
Shares Out.: $86.21M

$211.92M in TTM revenue declined 16.7% YoY, reaching $72.51M last quarter. TTM EBITDA of $-1.91M and TTM operating income of $-18.20M show growth is flowing through to the bottom line. TTM net income of $40.22M means revenue is converting into profit. Across the last 8 quarters, TTM revenue has risen for 2 consecutive quarters — an improving trend.

Margins

Gross, EBITDA, operating, and net margin trends

Gross Margin: 21.0%
EBITDA Margin: 4.3%
Op. Margin: -7.5%
Net Margin: -14.5%

Op. margin of -7.5% is down 0.5% YoY — costs are rising relative to revenue. Net margin at -14.5% and gross margin of 21.0% show how much of each revenue dollar survives to profit. Over the past year, operating margin is down 7% — a weakening trend.

Price Ratios

P/E, P/S, P/B, EV/EBITDA, FCF yield, and earnings yield

P/E Ratio: 11.5x
P/S Ratio: 2.2x
P/B Ratio: 1.7x

At 11.5x P/E, the stock trades below typical market levels. P/S of 2.2x and P/B of 1.7x provide additional context. Use the growth and margin sections to judge whether the multiple is justified. Over the past year, P/E is up 0% — a weakening trend.

Assets & Liabilities

Total assets, cash, debt, book value, and leverage

Total Assets: $332.70M
Cash: $16.32M
Long-Term Debt: N/A
Book Value: $279.32M
D/E Ratio: N/A
Debt/EBITDA: 0.0

Cash Flow

Operating cash flow, free cash flow, FCF margin, and earnings quality

Op. Cash Flow: $5.69M
TTM Free Cash Flow: $-48.38M
FCF Margin: -22.8%
FCF / Net Income: -1.2

TTM FCF of $-48.38M on $5.69M in operating cash flow. The FCF / Net Income ratio of -1.2x means the business consumes cash — it is not yet self-funding. Across the last 8 quarters, free cash flow has risen for 2 consecutive quarters — an improving trend.